Arrowhead Pharmaceuticals, Inc.
ARWR
#1688
Rank
$12.589 B
Marketcap
United States
Country
$89.12
Share price
-0.13%
Change (1 day)
188.98%
Change (1 year)
Categories
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational…
Key Metrics
Trailing P/E
—
Forward P/E
-17.24
EPS (TTM)
$-2.28
Forward EPS
$-4.80
Price / Book
25.12
EV / EBITDA
-57.2x
Beta
1.28
Dividend Yield
—
Return on Equity
-55.21%
Return on Assets
-8.10%
Debt / Equity
295.98
Current Ratio
5.90
Gross Margin
100.00%
Operating Margin
-226.03%
Net Profit Margin
-47.79%
Free Cash Flow
$-48,628,124
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 14 – Sep 11
-4.37%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$829.448M
Latest Net Income$-1,631,000
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Arrowhead Pharmaceuticals, Inc. with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
ARWR
No recent news available. Set FINNHUB_API_KEY to enable news.
